Compare Goldman Sachs Physical Gold ETF (AAAU) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs BioNTech SE - ADR — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.48, while BioNTech SE - ADR trades at $92.9 (market cap $23.31B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AAAU | BNTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $119.34 |
52-Week Low | $32.74 | $83.89 |
Market Cap | — | $23.31B |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU trades at $43.42, up 0.35% today, with a bullish technical signal from moving averages but bearish oscillators. Key support is at $42 and resistance at $44. Recent news highlights gold's strength amid cooling U.S. inflation and geopolitical tensions, with spot gold reaching $4,438/oz. Financial ratios are unavailable, limiting fundamental assessment.
The outlook for AAAU is supported by positive gold market dynamics, including central bank demand and inflation trends. Risks include potential Fed policy shifts and market volatility. Analyst sentiment is mixed, with technical indicators suggesting caution despite bullish momentum.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
